OBI Pharma’s OBI-999 Receives the US FDA’s Orphan Drug Designation to Treat Gastric Cancer

Shots:

• The US FDA has granted ODD to the OBI-999 for the treatment of gastric cancer. This marks the second ODD to the therapy as it has already received the FDA’s ODD to treat pancreatic cancer on Dec 26, 2019
• The US FDA grants ODD to therapies intended to treat, diagnose or prevent rare diseases or disorders affecting fewer than 200,000 people in the US
• OBI-999 is a novel ADC in combination with a validated payload (MMAE) and the antibody targeting Globo H, currently being evaluated in P-I/II clinical study and has demonstrated tumor shrinkage in its preclinical studies

Click here ­to­ read full press release/ article | Ref:  OBI Pharma | Image:  OBI Pharma